Pharvaris N.V.
Status: Publicly traded
Direct answer
Pharvaris N.V. is publicly traded on NASDAQ under the ticker PHVS.
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule...
Can you invest in Pharvaris N.V.?
Yes. Pharvaris N.V. is publicly traded on NASDAQ under the ticker PHVS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Pharvaris N.V.
Detailed equity research is provided by MarketSnap.